Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report details a specific share repurchase transaction executed on May 17, 2013, pursuant to authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 119,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,700.0 pence per share; lowest price paid was 1,696.0 pence per share.
- Treasury Holdings (Settled): 499,023,804 shares, representing 9.20% of total issued share capital.
- Treasury Holdings (Including Unsettled): 499,435,304 shares, representing 10.14% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,927,116,905 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 119,500 shares on May 17, 2013. This transaction increased the proportion of shares held in Treasury to 10.14% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (499,023,804 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.14% held in Treasury including unsettled shares).
- Check the number of shares in issue (4,927,116,905) to ensure accurate denominator usage for disclosure thresholds under FSA rules.
- Note that this filing does not contain operational or financial performance data for the period.